Overview: SMN2 Copy Number TestIntroduction: The SMN2 Copy Number Test measures SMN2 copy number to assess spinal muscular atrophy severity, helping guide treatment for muscle weakness. Affecting 1 in 10,000 newborns, spinal muscular atrophy severity varies with SMN2 copies, posing diagnostic challenges. Following 2023 Muscular Dystrophy Association (MDA) guidelines, it uses PCR for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: SMN2 Copy Test, SMA Severity Assay.
FDA Status: FDA-approved test, meeting pathology standards for diagnostic reliability.
Historical Milestone: SMN2 copy number testing began in the 2000s with research by Prior, who linked copies to severity. PCR advancements by Roche improved detection, surpassing earlier MLPA methods.
Purpose: Measures SMN2 copy number to assess spinal muscular atrophy severity, guides gene therapy or supportive care, and evaluates patients with muscle weakness, aiming to manage disease.
Test Parameters: SMN2 copy number
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of muscle issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document muscle weakness. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., respiratory failure), and sample collection risks.
Procedural Considerations: Uses PCR to measure copies, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Higher copy number suggests milder severity, guiding therapy. Early treatment might improve outcomes, while low copies indicate severe disease. Normal results may require other tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: Electromyography, SMN1 testing, or muscle biopsy to confirm diagnosis.
Test Limitations: Specific to SMN2; correlation with clinical status needed. False negatives possible with technical errors.
References: MDA Guidelines, 2023; Human Mutation, Prior TW, 2022.
